Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Thursday. The brokerage issued a sell rating on the stock.

Oragenics Stock Performance

Shares of NYSE OGEN opened at $0.31 on Thursday. The firm has a market cap of $3.75 million, a P/E ratio of -0.04 and a beta of 0.40. Oragenics has a 1 year low of $0.25 and a 1 year high of $4.95. The firm’s 50 day moving average price is $0.33 and its 200 day moving average price is $0.58.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.